Clinical Trial

Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer

Study acronym: DECIPHER
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 12, 2024 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
Multicentre, single arm, open label UK phase II trial to assess the efficacy of trastuzumab deruxtecan in reducing micrometastatic disease burden in HER2 positive GOA patients who are ctDNA positive after chemotherapy and surgery. 25 patients will be recruited from approximately 15 NHS secondary care sites.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-07-27; most recent amendment 2024-11-07.
Status change: Not Yet Recruiting → Recruiting 2024-04-17
Trial Details
NCT Number NCT05965479
Lead Sponsor University of Southampton
Collaborators: AstraZeneca, Natera, Inc.
Conditions Gastrooesophageal Cancer
Enrollment 25 participants
Start Date 2024-04-10
Primary Completion 2026-03-31 (estimated)
Study Completion 2028-04-30 (estimated)
Updated on ClinicalTrials.gov 2024-11-12